PROFOUND MEDICAL CORP. (PROF) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$11.07M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$8.02M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$8.91M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$13.81M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$11.07M | (m) | (m) | (m) | (m) | -$11.34M* | (m) | $5.65M | $7.36M | $55.00K |
| 2026-03-31 | Reported | (m) | -$8.02M | (m) | (m) | (m) | (m) | -$8.58M | (m) | $5.26M | $6.59M | $25.00K |
| 2025-09-30 | Reported | (m) | -$8.91M | (m) | $5.06M | (m) | (m) | -$9.61M* | (m) | $5.42M | $7.43M | $121.00K |
| 2025-06-30 | Reported | (m) | -$13.81M | (m) | $1.98M | (m) | (m) | -$13.74M* | (m) | $6.10M | $9.33M | $64.00K |
| 2025-03-31 | Reported | (m) | -$11.17M | (m) | $2.34M | (m) | (m) | -$8.28M | (m) | $4.81M | $8.21M | $41.00K |
| 2024-09-30 | Reported | (m) | -$9.00M | (m) | $2.54M | (m) | (m) | -$6.83M* | (m) | $4.17M | $6.62M | $177.00K |
| 2024-06-30 | Reported | (m) | -$7.84M | (m) | $1.95M | (m) | (m) | -$6.22M* | (m) | $4.21M | $5.06M | $19.00K |
| 2024-03-31 | Reported | (m) | -$7.88M | (m) | $1.22M | (m) | (m) | -$4.53M | (m) | $3.94M | $4.80M | $40.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$41.25M | (m) | (m) | (m) | $176.00K | -$38.21M | (m) | $20.60M | $32.05M | $252.00K |
| 2024-12-31 | Reported | (m) | -$33.06M | (m) | $9.74M | (m) | (m) | -$23.45M | (m) | $16.96M | $23.13M | -$2.00K |
| 2023-12-31 | Reported | (m) | -$28.65M | (m) | $5.90M | (m) | (m) | -$22.61M | (m) | $14.42M | $18.54M | -$128.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |